Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Illumina, Inc.Trade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while DENTSPLY SIRONA Inc trades at $11.69 (market cap $2.32B). The key difference: Illumina, Inc. is far larger — about 12.5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

ILMNXRAY
Market Cap
$28.96B$2.32B
Sector
HealthHealth
52-Week High
$205.10$14.68
52-Week Low
$91.00$9.64
Enterprise Value
$30.32B$4.40B
Dividend Yield
5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.

The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $12.12, down 7.97% in 24 hours, with a bearish technical signal and support near $12. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Financials show negative net income margins and ROE, though gross margins remain solid at 49.52%. Recent news highlights institutional stake increases and strategic partnerships, such as the expanded Medline Sinclair relationship in Canada.

The outlook is cautious due to persistent revenue declines and profitability challenges, offset by cost-cutting efforts and digital dentistry growth. Risks include weak European demand and high debt levels, while analyst consensus is Hold with a $11.50 price target, indicating limited near-term upside amid turnaround execution uncertainties.

Returns comparison

Trailing returns across standard periods

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY